Keywords:
Neoplasia, Imaging sequences, Computer Applications-General, MR, Neuroradiology brain, MR physics, Molecular imaging
Authors:
A. Deshmane1, M. Zaiss1, K. Herz1, M. Rivlin2, A. Kujawa3, M. Kim3, G. Navon2, X. Golay3, K. Scheffler1; 1Tuebingen/DE, 2Tel Aviv/IL, 3London/UK
DOI:
10.26044/ecr2019/C-1311
Aims and objectives
Chemical exchange saturation transfer (CEST) magnetic resonance imaging (MRI) allows for indirect detection of diluted molecules via their saturation transfer to the abundant water pool [1-3].
Many different diluted solutes were reported to be detectable with CEST,
including endogenous solutes such as peptides and proteins [3–6],
creatine [7,
8],
glutamate [9,
10],
and injected solutes such as iopamidol [11–13],
or glucose [14–17].
CEST MRI is gaining interest as a molecular MRI technique in a clinical setting. To meet the demand for a fast CEST sequence providing volume coverage in a clinically feasible scan time,
the snapshot CEST [18] sequence was recently developed to provide flexible CEST saturation with a fast 3D imaging readout.
In this study,
snapshot CEST protocols implemented on clinical scanners with field strength of 3 T were tested for clinical feasibility in three different CEST contrasts and evaluation methods.
Reproducibility of each acquired CEST contrast was evaluated at three clinical sites.